Create
Learn
Share

Diabetes 6-21-16

rename
ruhland1's version from 2016-06-22 18:38

Section

Question Answer
victozaGLP 1 (liraglutide)
byettaexenatide
truclitydulaglutide
Invokanacanagliflozin, SGLT-2 inhibitor
GLP-1 ag s/eGI upset, pancreatitis
GLP-1 ag MOAup insulin sec, dn glucagon sec, slows down gastric empty
sitagliptinDPP-4 inh
DPP-4 inh MOAup incretins * dn glucaon and up insulin
DPP-4 inh S/Eheadache, nausea, skin reactions
TZD-glitazones
TZD moaactivate PPARs * repress DNA transcription of genes that increase storage of fatty acids, dn insulin resistance
TZD effectsdn insulin resistance
TZD s/eperiphreal edema, hepatitis
memorize

Section 2

Question Answer
InvokanaSGLT 2 inh (canagliflozin)
JardianceSGLT2 inh (empagliflozin)
SGLT2 s/eUTI, ketoacidosis
entry A1c less than7.5%Metformin > GLP1 > SGLT2 > DPP4i > AGi (monotherapy)
acarbosealpha glucosidase inh
miglitolalphaglusidase inhibitor
entry A1c >7.5%Metformin and 1 of the above
colesevalambile acid sequestrants used in entry >7.5%
glipizidesulfonurea
sulfonurea MOAblock K ch * up Ca ch * up Ca influx * up insulin release
entry >9.0% and no sxdual or triple therapy
entry >9.0% and sxinsulin + other
flow of things if less than 7.5% entrymonotherapy 3 mo -> dual (metf + 1) 3 mo -> Metf +2 3mo -> add or intensify insulin
memorize

Recent badges